SynthesisOncotarget2016
Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Prognostic value of lymphocyte-to-monocyte ratio for breast cancer: a systematic review and meta-analysis.BMC women's health · 2025Pooled it
- Can posttreatment blood inflammatory markers predict poor survival in gynecologic cancer?: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Preoperative systemic inflammatory markers as prognostic factors in differentiated thyroid cancer: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2023Pooled it
- Prognostic Role of Pretreatment C-Reactive Protein to Albumin Ratio in Urological Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis.BMC cancer · 2019Pooled it
- Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.British journal of haematology · 2018Trial
- Association of the glucose-to-lymphocyte ratio with all-cause and cardiovascular disease mortality in U.S. adults: A population-based cohort study.Clinics (Sao Paulo, Brazil) · 2026Article
- "Prognostic Significance of Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and Monocyte-to-Lymphocyte Ratios in Myeloid Neoplasms: A Systematic Review".Health science reports · 2026Review
- Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Recurrence in HPV-Associated Oropharyngeal Cancer After Transoral Robotic Surgery.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- A New Diagnostic Approach Using the NLR/LMR Ratio in the Differential Diagnosis of Neck Masses: Hematologic Evaluation of Patients With Cervical Lymphadenopathy.Journal of clinical laboratory analysis · 2026Article
- Prognostic Value of Pre-Treatment Systemic Inflammatory Markers in Pediatric Unilateral Wilms Tumor.Cancers · 2026Article
- Artificial intelligence-driven CT radiomics model predicts prognosis in TACE-refractory hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Preoperative Systemic Inflammatory Marker Profile in Surgically Treated Intradural Spinal Tumors: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Evaluation of the predictive and prognostic potential of blood immune cell profiles in metastatic cancer patients treated with immune checkpoint inhibitors.Cancer immunology, immunotherapy : CII · 2026Article
- Prognostic value of pre-treatment serum CA19-9 and lymphocyte-to-monocyte ratio in HR+/HER2- breast cancer: a retrospective cohort study.BMC cancer · 2026Article
- A prognostic nomogram integrating Epstein-Barr virus DNA and specific inflammatory indices for early recurrent or metastatic nasopharyngeal carcinoma after first-line nedaplatin-based therapy.Discover oncology · 2026Article
- Systemic inflammatory ratios and their added value to cytology in cervical cancer detection: a multicenter study.Frontiers in medicine · 2026Article
- Dynamic remodeling of the tumor immune microenvironment: immunometabolic regulatory networks of astragalus polysaccharides and astragaloside IV.Frontiers in pharmacology · 2026Review
- Clinical utility of CBC-Derived inflammatory markers for predicting IVIG resistance: findings from a Korean infant Kawasaki disease cohort.Pediatric rheumatology online journal · 2025Article
- Inflammation-Based Hematologic Indices as Prognostic Markers in Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension: A Hypothesis-Generating Registry Study.International journal of molecular sciences · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation influences cancer development and progression, and a low lymphocyte to monocyte ratio (LMR) has been reported to be a poor prognostic indicator in several malignancies. Here we quantify the prognostic impact of this biomarker and assess its consistency in various cancers. Eligible studies were retrieved from PubMed, Embase and Web of Science databases. Overall survival (OS) was the primary outcome, cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), and progression-free survival (PFS) were secondary outcomes. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated. Fifty-six studies comprising 20,248 patients were included in the analysis. Overall, decreased LMR was significantly associated with shorter OS in non-hematological malignancy (HR: 0.59, 95% CI: 0.53-0.66; P < 0.001) and hematological malignancy (HR: 0.44, 95% CI: 0.34-0.56; P < 0.001). Similar results were found in CSS, DFS, RFS and PFS. Moreover, low LMR was significantly associated with some clinicopathological characteristics that are indicative of poor prognosis and disease aggressiveness. By these results, we conclude that a decreased LMR implied poor prognosis in patients with cancer and could serve as a readily available and inexpensive biomarker for clinical decision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.